Table 2.
Comparison of Surveillance Interval Recommendations for Serrated Polyps Provided in the 5 Guidelines
| Baseline colonoscopy finding | 2020 USMSTF | 2020 BSG/ACPGBI/PHE | 2020 ESGE | 2021 JGESc | 2022 Korea |
|---|---|---|---|---|---|
| ≤ 20 HPs in rectum or sigmoid colon < 10 mm or ≤ 20 HPs proximal to sigmoid colon < 10 mm | 10 yr | No recommendation | No recommendation | No recommendation | No recommendation |
| HP > 10 mm | 3–5 yr | No recommendation | No recommendation | No recommendation | 3 yrd |
| 1–2 SSLs < 10 mm | 5–10 yr | Return to screening | Return to screening | No recommendation | 5–10 yr |
| 3–4 SSLs < 10 mm | 3–5 yr | Return to screening | Return to screening | No recommendation | 3–5 yr |
| 5–10 SSLs < 10 mm | 3 yr | 3 yr | No recommendation | No recommendation | 3 yr |
| SSL ≥ 10 mm | 3 yr | 3 yra | 3 yr | No recommendation | 3 yr |
| SSL with dysplasia | 3 yr | 3 yra | 3 yr | No recommendation | 3 yr |
| TSA | 3 yr | 3 yra | 3 yr | No recommendation | 3 yr |
| Piecemeal resection of SSL > 20 mm | 6 mo | 2–6 mob | 3–6 mo | No recommendation | 6 mo |
| SPS | No recommendation | Referred to BSG hereditary CRC guidelines (1–2 yr) | No recommendation | 1 yr | No recommendation |
The BSG/ACPGBI/PHE recommends surveillance after 3 years in the presence of 2 or more precancerous polyps.
The BSG/ACPGBI/PHE recommends checking the site once more 18 months after the original excision.
The JGES proposes surveillance intervals of 3–5 years for SSL without considering size and number.
The Korean guidelines recommend a 3-year surveillance interval for serrated polyps ≥10 mm regardless of whether they are HPs or SSLs.
USMSTF, U.S. Multi-Society Task Force; BSG, British Society of Gastroenterology; ACPGBI, Association of Coloproctology of Great Britain and Ireland; PHE, Public Health England; ESGE, European Society of Gastrointestinal Endoscopy; JGES, Japan Gastroenterological Endoscopy Society; HP, hyperplastic polyp; SSL, sessile serrated lesion; TSA, traditional serrated adenoma; SPS, serrated polyposis syndrome; CRC, colorectal cancer.